Cargando…
TAT-fused IP3R-derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca(2+) release
Ovarian cancer is the most common gynecological malignancy. At present, cisplatin is used to treat ovarian cancer; however, the development of cisplatin resistance during therapy is a common obstacle to achieving favorable outcomes. Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reporte...
Autores principales: | Xie, Qi, Xu, Ye, Gao, Weinan, Zhang, Yong, Su, Jing, Liu, Yanan, Guo, Yuting, Dou, Minghan, Hu, Kebang, Sun, Liankun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752180/ https://www.ncbi.nlm.nih.gov/pubmed/29207009 http://dx.doi.org/10.3892/ijmm.2017.3260 |
Ejemplares similares
-
Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis
por: Orzechowska, Emilia Joanna, et al.
Publicado: (2014) -
ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells
por: Xu, Yunjie, et al.
Publicado: (2018) -
Selective modulation of subtype III IP(3)R by Akt regulates ER Ca(2+) release and apoptosis
por: Marchi, S, et al.
Publicado: (2012) -
Termination of Ca(2+) Release for Clustered IP(3)R Channels
por: Rüdiger, Sten, et al.
Publicado: (2012) -
PINK1 and Parkin regulate IP(3)R-mediated ER calcium release
por: Ham, Su Jin, et al.
Publicado: (2023)